Janssen's Yondelis gains priority review in soft tissue sarcoma
This article was originally published in Scrip
Executive Summary
Johnson & Johnson subsidiary Janssen Research & Development was granted a priority review by the FDA for Yondelis (trabectedin) as a treatment for patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy, including an anthracycline.